Actinium Pharmaceuticals, Inc. (ATNM), Monday announced that its Iomab-B Phase 3 SIERRA trial results demonstrated survival benefit in high-risk relapsed or refractory acute myeloid leukemia patients with TP53 mutations.
Iomab-B significantly improved outcomes in TP53 positive patients with a median overall survival of 5.49 months versus 1.66 months in those not receiving Iomab-B (hazard ratio = 0.23, p-value=0.0002) in
Actinium Pharma (ATNM) Highlights Improved Survival with Iomab-B streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Actinium Pharma (ATNM) Appoints Lynn Bodarky as Chief Business Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today.